WallStSmart
INO

Inovio Pharmaceuticals Inc

NASDAQ: INO · HEALTHCARE · BIOTECHNOLOGY

$1.12
+0.00% today

Updated 2026-04-30

Market cap
$95.46M
P/E ratio
P/S ratio
1,460.95x
EPS (TTM)
$-1.81
Dividend yield
52W range
$1 – $3
Volume
1.8M

Inovio Pharmaceuticals Inc (INO) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+26.4%
Last 4 quarters
Revenue YoY growth
-155.9%
Most recent quarter
EPS YoY growth
+53.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-4.3%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.7%
2025-11-10
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-13$-0.28+19.6%$1.68$1.63-3.0%
2025-11-10$-0.87+12.1%$2.12$2.00-5.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.35$-0.28+19.6%$-65343.00-155.9%
2025-09-30$-0.99$-0.87+12.1%
2025-06-30$-1.07$-0.61+43.0%
2025-03-31$-0.74$-0.51+31.1%$65343.00
2024-12-31$-0.83$-0.60+27.9%$116994.00+14.0%
2024-09-30$-1.15$-0.89+22.6%
2024-06-30$-1.10$-1.19-8.2%$100762.00-55.4%
2024-03-31$-1.00$-1.31-31.0%
2023-12-31$-1.27$-1.12+11.8%$102651.00
2023-09-30$-0.13$-0.13+0.0%$388446.00
2023-06-30$-0.14$-0.13+7.1%$225971.00
2023-03-31$-0.14$-0.16-14.3%$114943.00

Frequently asked questions

Has Inovio Pharmaceuticals Inc beaten earnings estimates?
Inovio Pharmaceuticals Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +26.4% over the last 4 quarters.
How does INO stock react to earnings?
INO stock has moved an average of -4.3% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Inovio Pharmaceuticals Inc's revenue growth rate?
Inovio Pharmaceuticals Inc reported year-over-year revenue growth of -155.9% in its most recent quarter, with EPS growing +53.8% year-over-year.